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Abstract
Purpose: Review calcium homeostasis in pregnancy and provide evidence-based best practice recommendations for 
the management of hypoparathyroidism in pregnancy. 
Methods: We searched MEDLINE, EMBASE and Cochrane databases from January 2000 to April 1, 2018. A total of 65 
articles were included in the final review. 
Conclusions: During pregnancy, calcitriol levels increase by two- to—three-fold resulting in enhanced intestinal calcium 
absorption. The renal filtered calcium load increases leading to hypercalciuria. PTHrP production by the placenta and 
breasts increases by three-fold, and this may lower the doses of calcium and calcitriol required during pregnancy 
in mothers with hypoparathyroidism. The literature however describes a wide variation in the required doses of 
calcium and calcitriol during pregnancy in hypoparathyroid mothers, with some women requiring higher doses of 
calcitriol, whereas others require lower doses. Close monitoring is necessary as hypercalcemia in the mother may 
suppress the fetal parathyroid gland development. Also hypocalcemia in the mother is harmful as it may result in 
secondary hyperparathyroidism in the fetus. This may be associated with demineralization of the fetal skeleton and 
the development of intrauterine fractures. Inadequate treatment of hypoparathyroidism may also result in uterine 
contractions and an increased risk of miscarriage. Treatment targets during pregnancy are to maintain a low normal 
serum calcium. Calcium, calcitriol and vitamin D supplements are safe during pregnancy. Close monitoring of the 
mother with a multidisciplinary team is advised for optimal care. If calcium homeostasis is well controlled during 
pregnancy, most women with hypoparathyroidism have an uncomplicated pregnancy and give birth to healthy babies.
Introduction and methodology
Hypoparathyroidism is a rare condition and when it 
occurs in pregnancy it maybe associated with significant 
maternal and fetal morbidity (1, 2). Physiologic changes 
in the calcium regulating hormones, which occur during 
pregnancy impact calcium homeostasis and necessitate 
close monitoring of serum calcium during pregnancy in 
hypoparathyroid mothers. Frequent adjustments in the 
dose of calcium and calcitriol may be required in order 
to avoid both hypocalcemia and hypercalcemia. Both 
these conditions impact fetal parathyroid development 
and may result in maternal and fetal morbidity. We 
reviewed the literature and provided evidence-based 
Correspondence 
should be addressed 
to A Khan 
Email 
aliya@mcmaster.ca
European Journal of 
Endocrinology  
(2019) 180, R37–R44
-18-0541
Review
180
2
https://eje.bioscientifica.com
https://doi.org/10.1530/EJE-18-0541
Published by Bioscientifica Ltd.
Printed in Great Britain
© 2019 European Society of Endocrinology
Downloaded from Bioscientifica.com at 03/25/2019 10:04:58AM
via Azienda Ospedaliero Universitaria Careggi Firenze, Universitaria Careggi and Univ Degli Studi Di Firenze
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
180:2 R38Review A Khan and others Hypoparathyroidism in 
pregnancy
https://eje.bioscientifica.com
recommendations guiding clinical practice today. 
MEDLINE, EMBASE and CENTRAL databases were 
searched from January 1, 2000 to April 1, 2018 using 
the MeSH search terms hypoparathyroidism, pregnancy, 
physiology, complications and management. A total 
of 1449 articles were found. These were reduced to 123 
articles based on abstract and title. We excluded letters 
and editorials and only included English language papers 
dealing with humans. Case reports and case series were 
also included due to the limited evidence available in the 
literature today. The final review included 65 articles.
Impact of pregnancy on 
calcium homeostasis
During pregnancy serum albumin decreases with the 
expansion of intravascular volume. This reduction in 
serum albumin results in a reduction in the measured 
total albumin-bound calcium. Longitudinal studies 
have demonstrated that serum ionized calcium as well 
as calcium corrected for albumin remain in the normal 
reference range (3, 4, 5). Serum phosphorus is unchanged 
during pregnancy (3, 4, 5). Parathyroid hormone (PTH) is 
suppressed into the low normal reference range and may 
actually decline below the normal reference range in the 
1st trimester (3, 4, 5, 6, 7, 8, 9, 10). PTH subsequently rises 
into the midnormal reference range by the third trimester 
as observed in longitudinal studies. PTH is affected by 
maternal dietary calcium intake as well as maternal 
vitamin D levels (11).
Calcitriol rises in the first trimester and increases by 
two- to three-fold by term as noted in longitudinal studies 
(4, 5, 12, 13, 14, 15). This significant rise in calcitriol 
increases intestinal calcium absorption and suppresses 
PTH (11, 16, 17). The kidney is the main source for the 
rise in calcitriol with some contribution from the placenta 
and the fetus. Pregnancy is associated with an increase in 
renal expression of Cyp27b1 (1-alpha hydroxylase) with 
levels of Cyp27b1 being 35-fold higher in the kidneys 
than that found in the placenta (18). The kidney therefore 
appears to be the major source of the significant rise in 
serum calcitriol levels. This is also supported by the fact 
that anephric women on dialysis do not demonstrate 
significant rises in calcitriol during pregnancy (19).
The key stimulators of renal Cyp27b1 during 
pregnancy are not known and may be PTHrP. It is also 
possible that estradiol and prolactin may be contributing 
to the rise in Cyp27b1. PTHrP is known to be a weak 
stimulator of Cyp27b1 in comparison to PTH (20). The 
levels of 25hydroxyvitamin D levels appear to be stable 
during pregnancy despite increased conversion to 
calcitriol in addition to transfer of 25hydroxyvitamin D 
to the fetus (11).
Serum calcitonin rises during pregnancy and may 
protect the maternal skeleton from demineralization 
during pregnancy (3, 5, 11, 21, 22). Other investigators 
have not observed rises in serum calcitonin during 
pregnancy (9, 13). The source of the calcitonin appears to 
be the thyroid C-cells in addition the breast and placenta 
contribute to rises in serum calcitonin (23, 24). These rises 
in calcitonin have been observed in women who have 
previously had a total thyroidectomy (23, 24, 25).
Calcitonin levels may also increase in association with 
the rises in estradiol, estrone and estriol in pregnancy. 
Rises in calcitonin have also been observed in women 
using oral contraceptives and this may be secondary to 
the rises in estrogen (11, 26). Postmenopausal women on 
estrogen supplementation have also demonstrated rises in 
serum calcitonin (27).
PTHrP begins to rise from the third to the thirteenth 
week of gestation and increases by three-fold in comparison 
to the baseline pre-pregnancy level by term as noted in 
longitudinal studies (5, 8, 25, 28, 29) The significant rise 
in PTHrP may upregulate calcitriol and suppress PTH (11).
An important source for PTHrP appears to be the 
placenta. In a case report of a pregnant woman with 
severe hypercalcemia and very high levels of PTHrP, 
serum calcium normalized following cesarean section and 
delivery of the placenta (30). Post cesarean section the 
PTHrP levels also became undetectable (30). The breasts 
appear to be an important source of PTHrP. In a case of 
a pregnant woman with severe hypercalcemia and very 
high levels of PTHrP in the breast tissue, serum calcium 
normalized following bilateral mastectomy in the second 
trimester of pregnancy (31, 32). PTHrP also decreased post 
bilateral mastectomy and become undetectable following 
surgery (31, 32). High levels of estradiol may also increase 
PTHrP. In vitro studies have demonstrated that estradiol 
increases PTHrP mRNA expression in human endometrial 
cells (33).
In conclusion, rises in calcitriol during pregnancy 
lead to enhanced intestinal calcium absorption, which 
in turn increases renal filtered calcium load and results 
in increases in urine calcium (34; Fig. 1). The reductions 
in PTH (secondary to rises in calcitriol and PTHrP) 
also contribute to the hypercalciuria (16, 17, 34). The 
hypercalciuria observed during pregnancy has been 
associated with an increased risk of renal stones during 
pregnancy. The rises in calcitriol and PTHrP seen in 
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pregnancy in women with hypoparathyroidism may 
result in lower requirements for calcium and calcitriol 
supplements during pregnancy as noted in many case 
reports. However, the literature also contains many case 
reports of hypoparathyroid mothers in whom the calcium 
and calcitriol requirements have actually increased during 
pregnancy (35). Variations in requirements for calcium 
and calcitriol may be a reflection of variations in dietary 
calcium intake. Many of the patients in the reported 
cases requiring higher doses of calcitriol did not receive 
calcium supplements or had inadequate or unknown 
calcium intake (36, 37, 38, 39, 40). Inadequate calcium 
intake in the first trimester may contribute to inadequate 
mineral accrual necessary for the last trimester in order to 
meet the calcium requirements of the developing fetus. 
Also there may be variations in the production of PTHrP 
from the placenta and breast as well as the formation of 
calcitriol from the maternal kidneys and these variations 
may contribute to differences in dose requirements 
during pregnancy in women with hypoparathyroidism. 
Close monitoring is required during pregnancy to 
ensure that serum calcium is maintained in the normal 
reference range.
There are very limited data evaluating the effects 
of pregnancy in hypoparathyroid women on urinary 
calcium excretion. The limited data suggest that renal 
calcium excretion increases further with pregnancy in 
hypoparathyroidism (41).
What is the impact of maternal 
hypoparathyroidism on the 
developing fetus?
The endochondral skeleton of the embryo gradually 
mineralizes with approximately 80% of the mineral 
accruing in the third trimester (42, 43). The placenta is 
essential for the delivery of essential minerals namely 
calcium, phosphate and magnesium to the fetus from the 
maternal circulation. Even in the presence of inadequate 
maternal serum calcium the placenta will extract calcium 
to meet the fetal requirements at the expense of the 
maternal skeleton (44, 45, 46, 47). Fetal hypocalcemia 
does not develop until the maternal serum calcium is 
severely reduced. In severe hypoparathyroidism with 
severe hypocalcemia, the fetus can develop hypocalcemia. 
This will result in the stimulation of the fetal parathyroid 
glands and development of hyperparathyroidism and 
demineralization of the fetal skeleton (48, 49, 50, 51). 
Calcitriol does not cross the placenta and circulating 
calcitriol in the fetus is synthesized in the fetal kidneys or 
placenta (52, 53, 54). Maternal PTH also does not cross the 
placenta and PTH is synthesized in low concentrations in 
the fetal parathyroid glands (44, 54, 55, 56, 57, 58).
Calcitonin is synthesized in the fetal thyroid as well as 
the placenta (23, 59, 60). Cord blood has high levels of PTHrP 
from the placenta (61, 62). The serum calcium is normally 
maintained at a higher level in the fetus in comparison 
to the mother, and calcium, phosphorus and magnesium 
are actively transported against a concentration gradient 
by the placenta (63). These high levels of minerals may 
contribute to optimal skeletal calcification of the fetus 
(63). In the presence of maternal hypercalcemia, transfer 
of calcium to the fetus is increased and will result in the 
suppression of the fetal parathyroid glands (64). Similarly, 
in the presence of maternal hypocalcemia, placental 
transfer of calcium is decreased and will result in fetal 
parathyroid gland stimulation and the development of 
fetal hyperparathyroidism, with severe cases presenting 
with subperiosteal bone resorption, bowing of the long 
bones, osteitis fibrosa cystica, intrauterine rib and limb 
fractures, low birth weight, spontaneous abortion and 
possibly fetal death (65, 66, 67, 68).
What are the treatment targets for serum 
calcium during pregnancy?
During pregnancy, careful monitoring of serum calcium 
is required with maintenance of serum calcium in the 
PTHrP
PlacentaBreast
1,25 (OH) D
Bone 
resorption
Increases 
intestinal 
calcium + 
phosphate 
absorption
Increases Urine 
calcium
25 (OH) D
Figure 1
Calcium homeostasis during pregnancy.
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low normal reference range. It is recommended to 
avoid hypocalcemia in order to prevent stimulation 
of the fetal parathyroid glands (69). Hypercalcemia 
should also be avoided in order to prevent suppression 
of the fetal parathyroid glands, which can result in 
hypocalcemia in the newborn. Although several case 
reports have described normalization of serum calcium 
and PTH within the first months after birth, intrauterine 
hyperparathyroidism has been associated with skeletal 
demineralization and intrauterine fractures as mentioned 
above. Also intrauterine hypoparathyroidism has been 
associated with neonatal tetany (70, 71). Furthermore, 
untreated hypoparathyroidism has been associated with 
an increased risk of abortion (2). Therefore, it is important 
to maintain serum calcium in the low normal reference 
range during pregnancy and monitor closely to ensure 
that both hypocalcemia and hypercalcemia are avoided.
The lactating breast is a significant source of PTHrP 
and impacts bone resorption as well as enhances renal 
calcium reabsorption (12, 72). Calcitriol levels normalize 
postpartum, following delivery of the placenta. Also 
reductions in estradiol which are elevated by 100-fold 
in pregnancy and may have stimulated Cyp27b1 and 
this may contribute to the reductions in calcitriol levels 
(11). The effects of these changes on calcium homeostasis 
postpartum are variable and close monitoring of serum 
calcium is advised. However, care should be taken not to 
titrate (change) doses of calcitriol and calcium supplements 
too frequently, as this may contribute to wide fluctuations 
in serum calcium while adapting to the postpartum 
state. Serum albumin corrected or ionized calcium levels 
should be measured within the first week postpartum 
followed by measurement once-weekly during the first 
month postpartum. In the presence of breastfeeding we 
advise measuring calcium levels once a month. Calcium 
levels should be targeted in the low normal reference 
range similar to non-breastfeeding levels. More frequent 
measurements may of course be needed if calcium levels 
are out of the target range. If calcium levels have been 
fairly well controlled during pregnancy and the newborn 
thrives well, biochemical tests may not be needed. 
However, the newborn should be carefully monitored 
clinically and calcium levels should be evaluated in the 
baby if the baby is not well (e.g. does not suckle well) or 
if long periods of hypo- or hypercalcemia occurred during 
pregnancy, as this may have affected the development of 
the parathyroid glands of the newborn causing hypo- or 
hyper-calcemia.
As urinary calcium in hypoparathyroidism is closely 
related to serum calcium levels (34, 73), it is advised to 
maintain serum calcium levels in the lower part of the 
normal reference interval in order to avoid further rises in 
renal calcium excretion. Calcium, calcitriol and vitamin 
D supplements are safe to use during pregnancy. PTH 
has not been adequately evaluated in pregnancy and is 
classified as a pregnancy risk category C drug (74). Thiazide 
diuretics should be discontinued during pregnancy and 
are considered FDA pregnancy risk category B drugs (75).
What are the best treatment strategies for 
the management of hypoparathyroidism 
in pregnancy?
Since the publication of the first case of 
hypoparathyroidism in pregnancy (76) treatment options 
have not really improved despite a significant increase in 
our understanding of calcium homeostasis in both the 
mother and the fetus (1, 36, 37, 41, 68, 70, 77, 78, 79, 80, 
81, 82, 83, 84, 85). As noted previously the rises in calcitriol 
and PTHrP which occur in hypoparathyroid women 
during pregnancy may result in lower requirements for 
calcium and calcitriol supplementation; however, this 
may not always be the case and in some women calcium 
and calcitriol requirements may actually increase during 
pregnancy (35, 86). Close monitoring is required during 
pregnancy to ensure that serum calcium is maintained in 
the low normal reference range in order to avoid potential 
maternal and fetal complications. Calcium and calcitriol 
supplements are safe during pregnancy and lactation.
Recommendations
 • In order to avoid adverse effects on the development 
and function of the fetal parathyroid glands and to 
avoid worsening of renal calcium losses, serum calcium 
(albumin corrected or ionized) levels should be targeted 
toward the lower part of the normal reference range.
Quality of evidence – very low
 • We recommend monitoring serum calcium every 
3–4 weeks during pregnancy to ensure that hyper or 
hypocalcemia do not develop. If changes in the dose 
of calcium or calcitriol are advised, then the lab profile 
with serum calcium corrected for albumin should be 
repeated in 1–2 weeks. The half-life of calcitriol is 4–6 h 
and steady state is reached in five half-lives. Waiting for 
1–2 weeks provides us with an opportunity to observe 
the real-world response in the individual patient as 
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serum calcium will also be dependent on other factors 
including dietary and lifestyle factors such as exercise.
Quality of evidence – very low
 • We recommend serum phosphate, magnesium, 
25hydroxyvitamin D and the 24-h urine for calcium 
should be maintained in the normal reference range.
Quality of evidence – very low
 • We recommend stopping treatment with thiazides 
during pregnancy.
Quality of evidence – moderate
 • We recommend stopping replacement therapy with 
PTH (1–84) and PTH (1–34) during pregnancy.
Quality of evidence – low
 • We recommend educating the patient regarding the 
symptoms of hypercalcemia and hypocalcemia and 
advice that they have their serum calcium (corrected 
for albumin or ionized) checked urgently if they are 
experiencing symptoms of hypo or hypercalcemia. 
Optimal care outcomes for both the mother and 
baby are achieved with coordinated care among the 
endocrinologist, obstetrician as well as the pediatrician. 
We advise informing the pediatrician prior to delivery 
to ensure the neonate can be immediately assessed 
with appropriate monitoring of the serum calcium.
Quality of evidence – very low
In conclusion, hypoparathyroidism may result in 
severe adverse pregnancy outcomes if not adequately 
treated. Calcium, calcitriol and vitamin D supplements 
are safe to use during pregnancy. Serum calcium should be 
monitored every 3–4 weeks during pregnancy. Although 
only limited data are available in the form of case reports 
and case series most women with hypoparathyroidism 
have an uncomplicated pregnancy and give birth to 
healthy babies if serum calcium levels are maintained 
within the low-to-mid normal reference range throughout 
pregnancy. A coordinated approach to care among the 
treating endocrinologist, obstetrician, pediatrician and 
nursing staff is highly recommended. There is an urgent 
need for prospective studies in hypoparathyroidism 
in pregnancy in order to enhance the quality of care 
available today.
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